Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues

Blood

Volumn 104, Issue 8, 2004, Pages 2224-2234

  Murdoch, Craig ^a   Giannoudis, Athina ^a   Lewis, Claire E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; CX3C CHEMOKINE; CYTOKINE; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; GAMMA CHEMOKINE; GAMMA INTERFERON; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 19; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN;

ADENOCARCINOMA; ANGIOGENESIS; ANIMAL CELL; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; ESOPHAGUS CARCINOMA; FIBROSARCOMA; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; ISCHEMIA; LUNG NON SMALL CELL CANCER; MACROPHAGE MIGRATION; MELANOMA; MENINGIOMA; METASTASIS; MONOCYTE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA; TUMOR; TUMOR GROWTH; UTERINE CERVIX CANCER;

EID: 4944244259     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-1109     Document Type: Review

References (170)

1. Ross JA. The biology of the macrophage. In: Burke B, Lewis CE, eds. The Macrophage. Oxford, United Kingdom: Oxford University Press; 2002:P1-P72.
2. Kelly PM, Davison RS, Bliss E, McGee JO. Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer. 1988; 57:174-177.
3. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol. 1994;56:423-435.
4. Yamashiro S, Takeya M, Nishi T, et al. Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am J Pathol. 1994;145:856-867.
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4;71-78.
6. Mantovani A, Sozzani S, Locati M, et al. Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Novartis Found Symp. 2004;256:137-145.
7. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002;7:177-189.
8. Blankenstein T. The role of inflammation in tumour growth and tumour suppression. Novartis Found Symp. 2004;256:205-210.
9. Blankenstein T, Qin ZH, Liberia K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med. 1991;173:1047-1052.
10. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.
11. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254-265.
12. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449-6465.
13. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys. 2001;49:569-574.
14. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408-1416.
15. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today. 2000;6:157-162.
16. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28:29-35.
17. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol. 1997;150:1723-1734.
18. Silzle T, Kreutz M, Dobler MA, Brockhoff G, Knuechel R, Kunz S. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol. 2003;33:1311-1320.
19. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56: 4625-4629.
20. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79:991-995.
21. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 2000;192:150-158.
22. Onita T, Ji PG, Xuan JW, et al. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res. 2002;8:471-480.
23. Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol. 2003;163:1233-1243.
24. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol. 2001;70:478-490.
25. Bjomheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. ArteriosclerThromb Vase Biol. 1999;19: 870-876.
26. Hollander AP, Corke KP, Freemont AJ, Lewis CE. Expression of hypoxia-inducible factor 1 alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 2001;44:1540-1544.
27. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol. 1993;77:731-733.
28. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
29. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood. 2000;95:3032-3043.
30. Balkwill F. Chemokine biology in cancer. Semin Immunol. 2003;15:49-55.
31. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002;13:143-154.
32. Strieter RM, Belperio JA, Phillips RJ, Keane MP. Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp. 2004;256: 173-184.
33. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6: 3282-3289.
34. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest. 1995;95:2391-2396.
35. Graves DT, Barnhill R, Galanopoulos T, Antoniades HN. Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am J Pathol. 1992;140:9-14.
36. Arenberg DA, Keane MP, DiGiovine B, et al. Macrophage infiltration in human non-small-cell lung cancer: the role of CC Chemokines. Cancer Immunol Immunother. 2000;49:63-70.
37. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol (Berl). 1997;93:518-527.
38. Sato K, Kuratsu J, Takeshima H, Yoshimura T, Ushio Y. Expression of monocyte chemoattractant protein-1 in meningioma. J Neurosurg. 1995; 82:874-878.
39. Ohta M, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas, Int J Cancer. 2002;102:220-224.
40. Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC Chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999;59:4681-4687.
41. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001;7:285-289.
42. Mrowietz U, Schwenk U, Maune S, et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer. 1999; 79:1025-1031.
43. Tang RP, Kacinski B, Validire P, et al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biochem. 1990;44:189-198.
44. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727-740.
45. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med. 1995; 27:79-85.
46. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18:4-25.
47. Kao J, Ryan J, Brett G, et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem. 1992;267:20239-20247.
48. Clarijs R, Schalkwijk L, Ruiter DJ, de W. EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:1801-1806.
49. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003;88:163-166.
50. Grimshaw MJ, Wilson JL, Balkwill FR. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol. 2002;32:2393-2400.
51. Bottazzi B, Walter S, Govoni D, Colotta F, Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol. 1992;148:1280-1285.
52. Nesbit M, Schaider H, Miller TH, Hertyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol. 2001;166:6483-6490.
53. Locati M, Deuschle U, Massardi ML, et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol. 2002;168:3557-3562.
54. Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol. 2002;32:404-412.
55. Cross AK, Woodroofe MN. Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia. 1999;28:183-189.
56. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62:1093-1102.
57. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996; 3:895-904.
58. Mazzucchelli L, Loetscher P, Kappeler A, et al. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol. 1996;149:501-509.
59. Chetcuti A, Margan S, Mann S, et al. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate. 2001;47:132-140.
60. Scotton C, Milliken D, Wilson J, Raju S, Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br J Cancer. 2001;85:891-897.
61. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res. 2002;8:1108-1114.
62. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1-8.
63. Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation. 2003;10:359-370.
64. Patel L, Charlton SJ, Chambers JK, Macphee CH. Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine. 2001;14:27-36.
65. Moser B, Barella L, Mattel S, et al. Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem J. 1993;294(pt 1):285-292.
66. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398:718-723.
67. Di Marzio, Tse J, Landau NR. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res Hum Retroviruses. 1998;14:129-138.
68. Wang J, Guan E, Roderiquez G, Calvert V, Alvarez R, Norcross MA. Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages. J Biol Chem. 2001;276:49236-49243.
69. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
70. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002;62:5930-5938.
71. Begum NA, Coker A, Shibuta K, et al. Loss of hlRH mRNA expression from premalignant adenomas and malignant cell lines. Biochem Biophys Res Commun. 1996;229:864-868.
72. Shibuta K, Begum NA, Mori M, Shimoda K, Akiyoshi T, Barnard GF. Reduced expression of the CXC chemokine hlRH/SDF-1 alpha mRNA in hepatoma and digestive tract cancer. Int J Cancer. 1997;73:656-662.
73. Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 2002;86:1250-1256.
74. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167:1676-1686.
75. Kawasaki ES, Ladner MB. Molecular biology of macrophage colony-stimulating factor. Immunol Ser. 1990;49:155-176.
76. Rambaldi A, Young DC, Griffin JD. Expression of the M-CSF (CSF-1) gene by human monocytes. Blood. 1987;69:1409-1413.
77. Stanley ER, Guilbert LJ, Tushinski RJ, Bartelmez SH. CSF-1-a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem. 1983;21:151-159.
78. Csar XF, Wilson NJ, McMahon KA, et al. Proteomic analysis of macrophage differentiation. p46/52(Shc) Tyrosine phosphorylation is required for CSF-1-mediated macrophage differentiation. J Biol Chem. 2001;276:26211-26217.
79. Wang JM, Griffin JD, Rambaldi A, Chen ZG, Mantovani A. Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol. 1988;141:575-579.
80. Dorsch M, Hock H, Kunzendorf U, Diamantstein T, Blankenstein T. Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression. Eur J Immunol. 1993;23:186-190.
81. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000;60:2898-2905.
82. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336-3343.
83. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001;97:785-791.
84. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. FIM lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 1998;95:9349-9354.
85. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol. 2000;190:430-436.
86. Kao J, Houck K, Fan Y, et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem. 1994;269:25106-25119.
87. Knies UE, Kroger S, Clauss M. Expression of EMAP II in the developing and adult mouse. Apoptosis. 2000;5:141-151.
88. Knies UE, Behrensdorf HA, Mitchell CA, et al. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Proc Natl Acad Sci USA. 1998;95:12322-12327.
89. Masaki T, Ninomiya H, Sakamoto A, Okamoto Y. Structural basis of the function of endothelin receptor. Mol Cell Biochem. 1999;190:153-156.
90. Kusuhara M, Yamaguchi K, Nagasaki K, et al. Production of endothelin in human cancer cell lines. Cancer Res. 1990;50:3257-3261.
91. Cui P, Tani K, Kitamura H, et al. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J Leukoc Biol. 2001;70:306-312.
92. Bessis M, de Boisfleury C. Facts and speculation about necrotaxis (chemotaxis toward a dying cell). Blood Cells. 1984;10:5-22.
93. Laskin DL, Soltys RA, Berg RA, Riley DJ. Activation of alveolar macrophages by native and synthetic collagen-like polypeptides. Am J Respir Cell Mol Biol. 1994;10:58-64.
94. Lee AH, Dublin EA, Bobrow LG, Poulsom R. Invasive tabular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol. 1998;185:394-401.
95. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86-91.
96. Lal A, Peters H, Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 2001;93:1337-1343.
97. Bando H, Toi M, Kitada K, Koike M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed Pharmacother. 2003;57:333-340.
98. Koong AC, Denko NC, Hudson KM, et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000;60:883-887.
99. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001;7:437-443.
100. Raleigh JA, Calkins A, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 1998;58:3765-3768.
101. Janssen HL, Haustermans KM, Sprang D, et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head and-neck tumors. Int J Radiat Oncol Biol Phys. 2002;54:1537-1549.
102. Zhang FR, Schwarz MA. Pro-EMAP II is not primarily cleaved by caspase-3 and -7. Am J Physiol Lung Cell Mol Physiol. 2002;282:L1239-L1244.
103. Matschurat S, Knies UE, Person V, et al. Regulation of EMAP II by hypoxia. Am J Pathol. 2003; 162:93-103.
104. Grimshaw MJ, Naylor S, Balkwill FR. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther. 2002; 1:1273-1281.
105. Spinella F, Rosano L, Di C, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells. J Biol Chem. 2002;277:27850-27855.
106. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res. 2004;64:2461-2468.
107. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1 alpha is essential for myeloid cell-mediated inflammation. Cell. 2003;112:645-657.
108. Bosco MC, Puppo M, Pastorino S, et al. Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol. 2004;172:1681-1690.
109. Xu L, Xie K, Mukaida N, Matsushima K, Fidler IJ. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res. 1999;59:5822-5829.
110. Shi Q, Xiong Q, Le X, Xie K. Regulation of interleukin-8 expression by tumor-associated stress factors. J Interferon Cytokine Res. 2001;21:553-566.
111. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002;46:2587-2597.
112. Blades MC, Ingegnoli F, Wheller SK, et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID mice. Arthritis Rheum. 2002: 46:824-836.
113. Sica A, Saccani A, Bottazzi B, et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol. 2000;164: 733-738.
114. Negus RP, Turner L, Burke F, Balkwill FR. Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol. 1998;63:758-765.
115. Turner L, Scotton C, Negus R, Balkwill F. Hypoxia inhibits macrophage migration. Eur J Immunol. 1999;29:2280-2287.
116. Grimshaw MJ, Balkwill FR. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation-a potential mechanism. Eur J Immunol. 2001;31:480-489.
117. Seta KA, Kim R, Kirn HW, Millhorn DE, Beitner J. Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. J Biol Chem. 2001;276:44405-44412.
118. White JR, Harris RA, Lee SR, et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics. 2004;83:1-8.
119. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993;75:487-493.
120. Franklin CC, Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem. 1997;272:16917- 16923.
121. Ashida N, Arai H, Yamasaki M, Kita T. Differential signaling for MCP-1-dependent integrin activation and chemotaxis. Ann N Y Acad Sci. 2001;947: 387-389.
122. Wain JH, Kirby JA, Ali S. Leucocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1, -2, -3 and -4. Clin Exp Immunol. 2002;127:436-444.
123. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169-2177.
124. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med. 2003;198:1391-1402.
125. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003;425:307-311.
126. Sun Y, Cheng Z, Ma L, Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MARK activation. J Biol Chem. 2002;277: 49212-49219.
127. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998; 393:591-594.
128. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 2002;99: 2703-2711.
129. Penton-Rol G, Polentarutti N, Luini W, et al. Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN-gamma. J Immunol. 1998;160:3869-3873.
130. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA. 1966;56:72-77.
131. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966;153:80-82.
132. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179:1895-1902.
133. Meyer-Siegler K, Hudson PB. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 1996;48:448-452.
134. Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000;10:359-366.
135. Bacher M, Schrader J, Thompson N, et al. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol. 2003;162:11-17.
136. Burke B, Tang N, Corke KP, et al. Expression of HIF-1 alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol. 2002;196:204-212.
137. Heinrich SA, Messingham KA, Gregory MS, et al. Elevated monocyte chemoartractant protein-1 levels following thermal injury precede monocyte recruitment to the wound site and are controlled, in part, by tumor necrosis factor-alpha. Wound Repair Regen. 2003;11:110-119.
138. Burke-Gaffney A, Brooks AV, Bogle RG. Regulation of chemokine expression in atherosclerosis. Vascul Pharmacol. 2002;38:283-292.
139. Union MF, Fazio S. Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord. 2003;27(suppl 3):S35-S40.
140. DeVries ME, Ran L, Kelvin DJ. On the edge: the physiological and pathophysiological role of chemokines during inflammatory and immunological responses. Semin Immunol. 1999;11:95-104.
141. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med. 2002;6:357-376.
142. Capeans C, de Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina. 1998;18:546-550.
143. Abu el-Asrar AM, Van Damme J, Put W, et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol. 1997; 123:599-606.
144. Pufe T, Petersen W, Tillmann B, Mentlein R. Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. J Rheumatol. 2001;28:1482-1485.
145. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
146. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998:98:2108-2116.
147. Afuwape AO, Kiriakidis S, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol. 2002;17:961-972.
148. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198: 483-489.
149. Wu L, Yu YL, Galiano RD, Roth SI, Mustoe TA. Macrophage colony-stimulating factor accelerates wound healing and upregulates TGF-beta1 mRN A levels through tissue macrophages. J Surg Res. 1997;72:162-169.
150. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992;140:301-316.
151. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol. 1997;150:1687-1699.
152. Seitz M, Loetscher P, Fey MF, Tobler A. Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol. 1994;33:613-619.
153. Einer SG, Einer VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14:1045-1053.
154. Black CE, Huang N, Neligan PC, Forrest CR, Lipa JE, Pang CY. Vasoconstrictor effect and mechanism of action of endothelin-1 in human radial artery and vein: implication of skin flap vasospasm. J Cardiovasc Pharmacol. 2003;41:460-467.
155. Lipa JE, Neligan PC, Perreault TM, et al. Vasoconstrictor effect of endothelin-1 in human skin: role of ETA and ETB receptors. Am J Physiol. 1999;276:H359-H367.
156. Fan J, Unoki H, Iwasa S, Watanabe T. Role of endothelin-1 in atherosclerosis. Ann NY Acad Sci. 2000;902:84-93.
157. Best PJ, Lerman A. Endothelin in cardiovascular disease: from atherosclerosis to heart failure. J Cardiovasc Pharmacol. 2000;35:S61-S63.
158. Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST. Serum and synovial fluid concentrations of endothelin-1 in patients with rheumatoid arthritis. J Med. 1999;30:51-60.
159. Oku H, Kida T, Sugiyama T, Hamada J, Sato B, Ikeda T. Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. Retina. 2001;21:647-651.
160. Hennemann B, Beckmann G, Eichelmann A, Rehm A, Andreesen R. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother. 1998;45:250-256.
161. Lei H, Ju DW, Yu Y, et al. Induction of potent anti-tumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-gamma. Gene Ther. 2000;7:707-713.
162. Huang S, Xie K, Bucana CD, Ullrich SE, Bar E. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res. 1996;2: 1969-1979.
163. Bartholeyns J, Lopez M, Andreesen R. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results. Anticancer Res. 1991;11:1201-1204.
164. Faradji A, Bohbot A, Schmitt G, et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother. 1991;33:319-326.
165. Fantuzzi L, Borghi P, Ciolli V, Pavlakis G, Belardelli F, Gessani S. Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. Blood. 1999;94:875-883.
166. Fellowes R, Etheridge CJ, Coade S, et al. Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery. Gene Ther. 2000;7: 967-977.
167. Kashani-Sabet M, Liu Y, Fong S, et al. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA. 2002;99: 3878-3883.
168. Inoue S, Suzuki M, Nagashima Y, et al. Transfer of heme oxygenase 1 cDN A by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice. Hum Gene Ther. 2001;12:967-979.
169. Hashiba T, Suzuki M, Nagashima Y, et al. Adenovirus-mediated transfer of heme oxygenase-1 cDNA attenuates severe lung injury induced by the influenza virus in mice. Gene Ther. 2001;8: 1499-1507.
170. Griffiths L, Binley K, Iqball S, et al. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 2000;7:255-262.